FDA Approves Genentechs Evrysdi (risdiplam) for Treatment of Spinal Muscular Atrophy (SMA) in Adults and Children 2 Months and Older – Business Wire

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), revealed today that the U.S. Food and Drug Administration (FDA) has actually authorized Evrysd … [+14240 chars]